Thomas Zeller1, Ulrich Beschorner2, Ernst Pilger3, Marc Bosiers4, Koen Deloose4, Patrick Peeters5, Dierk Scheinert6, Karl-Ludwig Schulte7, Aljoscha Rastan8, Marianne Brodmann3. 1. Department of Angiology, Universitäts-Herzzentrum Freiburg-Bad Krozingen, Bad Krozingen, Germany. Electronic address: Thomas.zeller@universitaets-herzzentrum.de. 2. coreLab Bad Krozingen GmbH, Bad Krozingen, Germany. 3. Department of Angiology, Medical University Graz, Graz, Austria. 4. Department of Vascular Surgery, A.Z. Sint-Blasius, Dendermonde, Belgium. 5. Department of Cardiovascular & Thoracic Surgery, Imelda Hospital, Bonheiden, Belgium. 6. Department of Angiology, Park-Krankenhaus Leipzig, Leipzig, Germany. 7. Vascular Center Berlin, Ev. Krankenhaus Königin Elisabeth Herzberge, Berlin, Germany. 8. Department of Angiology, Universitäts-Herzzentrum Freiburg-Bad Krozingen, Bad Krozingen, Germany.
Abstract
OBJECTIVES: The aim of BIOLUX P-II (BIOTRONIK'S-First in Man study of the Passeo-18 LUX drug releasing PTA Balloon Catheter vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularization of infrapopliteal arteries) trial was to compare the safety and efficacy of a novel paclitaxel-coated drug-eluting balloon (DEB) versus an uncoated balloon (percutaneous transluminal angioplasty [PTA]) in de novo or native restenotic lesions of the infrapopliteal arteries in patients with claudication and critical limb ischemia. BACKGROUND:DEB have shown promising results in femoropopliteal lesions, but data for infrapopliteal lesions are scarce. METHODS: In this prospective, multicenter, randomized first-in-man study, 72 patients were randomized 1:1 to either a Passeo-18 Lux DEB (Biotronik AG, Buelach, Switzerland) (n = 36) or Passeo-18 PTA (n = 36). Follow-up assessments were scheduled at 1, 6, and 12 months, with angiographic assessment at 6 months. Adverse events were adjudicated by an independent clinical events committee, and angiographic parameters were assessed by an independent core laboratory. RESULTS: The primary safety endpoint (a composite of all-cause mortality, target extremity major amputation, target lesion thrombosis, and target vessel revascularization at 30 days) was 0% in the DEB group versus 8.3% in the PTA group (p = 0.239). The primary performance endpoint (patency loss at 6 months) was 17.1% in the DEB group versus 26.1% in the PTA group (p = 0.298), and major amputations of the target extremity occurred in 3.3% versus 5.6% of the patients at 12 months, respectively. CONCLUSIONS: The Passeo-18 Lux DEB has been proven to be safe and effective in infrapopliteal lesions with comparable outcomes to PTA.
RCT Entities:
OBJECTIVES: The aim of BIOLUX P-II (BIOTRONIK'S-First in Man study of the Passeo-18 LUX drug releasing PTA Balloon Catheter vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularization of infrapopliteal arteries) trial was to compare the safety and efficacy of a novel paclitaxel-coated drug-eluting balloon (DEB) versus an uncoated balloon (percutaneous transluminal angioplasty [PTA]) in de novo or native restenotic lesions of the infrapopliteal arteries in patients with claudication and critical limb ischemia. BACKGROUND: DEB have shown promising results in femoropopliteal lesions, but data for infrapopliteal lesions are scarce. METHODS: In this prospective, multicenter, randomized first-in-man study, 72 patients were randomized 1:1 to either a Passeo-18 Lux DEB (Biotronik AG, Buelach, Switzerland) (n = 36) or Passeo-18 PTA (n = 36). Follow-up assessments were scheduled at 1, 6, and 12 months, with angiographic assessment at 6 months. Adverse events were adjudicated by an independent clinical events committee, and angiographic parameters were assessed by an independent core laboratory. RESULTS: The primary safety endpoint (a composite of all-cause mortality, target extremity major amputation, target lesion thrombosis, and target vessel revascularization at 30 days) was 0% in the DEB group versus 8.3% in the PTA group (p = 0.239). The primary performance endpoint (patency loss at 6 months) was 17.1% in the DEB group versus 26.1% in the PTA group (p = 0.298), and major amputations of the target extremity occurred in 3.3% versus 5.6% of the patients at 12 months, respectively. CONCLUSIONS: The Passeo-18 Lux DEB has been proven to be safe and effective in infrapopliteal lesions with comparable outcomes to PTA.
Authors: Hong Kuan Kok; Hamed Asadi; Mark Sheehan; Frank P McGrath; Mark F Given; Michael J Lee Journal: Diagn Interv Radiol Date: 2017 Sep-Oct Impact factor: 2.630
Authors: Jesse Naghi; Ethan A Yalvac; Ali Pourdjabbar; Lawrence Ang; John Bahadorani; Ryan R Reeves; Ehtisham Mahmud; Mitul Patel Journal: Med Devices (Auckl) Date: 2016-06-28
Authors: Mariya Kronlage; Maximilian Wassmann; Britta Vogel; Oliver J Müller; Erwin Blessing; Hugo Katus; Christian Erbel Journal: Drug Des Devel Ther Date: 2017-10-06 Impact factor: 4.162
Authors: Marianne Brodmann; Thomas Zeller; Johnny Christensen; Christoph Binkert; Lubomir Spak; Henrik Schröder; Paolo Righini; Giovanni Nano; Gunnar Tepe Journal: J Vasc Bras Date: 2017 Oct-Dec